Bayer (FRA:BAYN) received a €100.00 ($119.05) price target from stock analysts at Barclays in a research note issued on Monday. The brokerage presently has a “sell” rating on the healthcare company’s stock. Barclays’ price target would suggest a potential downside of 5.41% from the company’s current price.
Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Bayer in a research note on Friday, October 20th. Sanford C. Bernstein set a €129.00 ($153.57) price target on Bayer and gave the company a “buy” rating in a report on Wednesday, January 17th. Independent Research set a €120.00 ($142.86) price target on Bayer and gave the company a “neutral” rating in a report on Friday, October 13th. Commerzbank set a €124.00 ($147.62) price target on Bayer and gave the company a “buy” rating in a report on Friday, October 13th. Finally, BNP Paribas set a €130.00 ($154.76) price target on Bayer and gave the company a “buy” rating in a report on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company. Bayer has an average rating of “Buy” and an average target price of €121.71 ($144.90).
Bayer (BAYN) traded up €1.64 ($1.95) during mid-day trading on Monday, hitting €105.72 ($125.86). The stock had a trading volume of 2,547,681 shares. Bayer has a fifty-two week low of €100.60 ($119.76) and a fifty-two week high of €123.82 ($147.40). The firm has a market capitalization of $86,910.00 and a price-to-earnings ratio of 28.34.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.